Synergistic effect of imatinib mesylate and fludarabine combination on Philadelphia chromosome-positive chronic myeloid leukemia cell lines

Turkish Journal of Hematology

Volumn 24, Issue 1, 2007, Pages 23-27

  Pişkin, Özden ^a   Özcan, M Ali ^a   Özsan, G Hayri ^a   Ateş, Halil ^a   Demirkan, Fatih ^a   Alacacioǧlu, Inci ^a   Ündar, Bülent ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

CML; Fludarabine; Imatinib mesylate; K562; Meg 01

Indexed keywords

CLADRIBINE; FLUDARABINE; IMATINIB;

ARTICLE; ASSAY; BLAST CELL; CELL KILLING; CELL PROLIFERATION; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; COLONY FORMING UNIT GM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LEUKEMIA CELL LINE; PHILADELPHIA CHROMOSOME POSITIVE CELL;

EID: 34547849594     PISSN: 13007777     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr/abl positive cells. Nat Med 1996;2:561-6.
2. Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997;90:3691-8.
3. Gora-Tybor J, Deininger MW, Goldman JM, Melo JV. The susceptibility of Philadelphia chromosome positive cells to FAS-mediated apoptosis is not linked to the tyrosine kinase activity of BCR/ABL. Br J Haematol 1998;103:716-20.
4. Dinndorf PA, Avramis VI, Wiersma S, Krailo MD, Liu-Mares W, Seibel NL, Sato JK, Mosher RB, Kelleher JF, Reaman GH. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group. J Clin Oncol 1997;15:2780-5.
5. Koryeka A, Smolewski P, Robak T. The influence of famesyl protein transferase inhibitor Rl15777 (Zarnestra) alone and in combination with purine nucleoside analogs on acute myeloid leukemia progenitors in vitro. Eur J Haematol 2004;73:418-26.
6. Hubeek I, Litvinova E, Peters GJ, Broekhuizen R, Haarman EG, Huismans DR, Cloos J, Zwaan CM, Fleischhack G, Creutzig U, Kaspers GJ. The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia. Int J Oncol 2004;25:1823-9.
7. Korycka A, Robak T. The influence of imatinib mesylate (ST1571) used alone or in combination with purine nucleoside analogues on the normal and chronic myelogenous leukaemia progenitor cells in vitro. Leuk Lymphoma 2003;44:1549-55.
8. Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y, Furukawa Y. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 2001;97:1999-2007.
9. Barteneva N, Stiouf I, Donato S, Kornblau S, Domain VD, Talpaz M. Altered interferon-a responsiveness in K562 cells pretreated with abl-tyrosine kinase inhibitor CGP57148B. Blood 1999;94:272b [abstract].
10. Thiesing JT, Ohno-Jones S, Kolibaba KS, Drucker BJ. Efficacy of an abl tyrosine kinase inhibitor in conjunction with other anti-neoplastic agents against bcr-abl positive cells. Blood 1999;94:100a [abstract].
11. Chou TC, Zhang XG, Balog A, Su DS, Meng D, Savin K, Bertino JR, Danishefsky SJ. Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. Proc Natl Acad Sci U S A 1998;95:9642-7.
12. Chou TC, Talalay P. Quantitative analyses of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
13. Clavio M, Venturino C, Pierri I, Garrone A, Miglino M, Canepa L, Balleari E, Balocco M, Michelis GL, Ballerini F, Gobbi M. Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia. Ann Hematol 2004;83:696-703. Epub 2004 Aug 18.
14. Giles FJ, Cortes JE, Kantarjian HM, O'Brien SM, Estey E, Beran M. A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia. Leuk Res 2004;28:353-7.